Belite Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Belite Bio (BLTE).

Price Target Range — 12 Quarters

Analyst Consensus — 8 Analysts

8Buy

Consensus RatingBuy# Analysts8Avg. Consensus PT$197Upside to Avg. PT+15.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 9, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$220→$234
Sep 8, 2026	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$214→$245
Sep 4, 2026	Canaccord Genuity	Whitney Ijem	Initiate	Buy	$303
Aug 14, 2026	Morgan Stanley	Judah Frommer	PT Raise	Overweight	$201→$206
Aug 14, 2026	Cantor Fitzgerald	Steve Seedhouse	PT Raise	Overweight	$266→$270
Aug 12, 2026	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$200→$214
Jun 15, 2026	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$200
May 26, 2026	Mizuho	Graig Suvannavejh	PT Cut	Outperform	$223→$215
May 21, 2026	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$200
Apr 22, 2026	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$200
Apr 13, 2026	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$200
Mar 3, 2026	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$185→$200
Mar 3, 2026	Morgan Stanley	Judah Frommer	PT Raise	Overweight	$191→$201
Mar 3, 2026	Cantor Fitzgerald	Steve Seedhouse	PT Raise	Overweight	$200→$266
Jan 28, 2026	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$185
Jan 26, 2026	B of A Securities	Tazeen Ahmad	Initiate	Buy	$195
Jan 6, 2026	Morgan Stanley	Judah Frommer	Initiate	Overweight	$191
Dec 2, 2025	Mizuho	Graig Suvannavejh	Upgrade	Neutral→Outperform	$105→$194
Dec 1, 2025	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$98→$185
Nov 24, 2025	Cantor Fitzgerald	Steve Seedhouse	Assumes	Overweight	$154

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $234

Mizuho analyst Graig Suvannavejh maintains Belite Bio (NASDAQ:BLTE) with a Outperform and raises the price target from $220 to $234.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $245

HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $214 to $245.

Benzinga Newsdesk

Why Is Belite Bio Stock Soaring Friday?

Canaccord Genuity initiates Belite Bio (BLTE) with a Buy and $303 target on FDA Priority Review for tinlarebant.

Vandana Singh

This PulteGroup Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday

Analysts initiated coverage: Hold on Lennar, Buys on Belite Bio, PulteGroup.

Avi Kapoor

PRO
Canaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303

Canaccord Genuity analyst Whitney Ijem initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $303.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Belite Bio, Raises Price Target to $206

Morgan Stanley analyst Judah Frommer maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $201 to $206.

Benzinga Newsdesk

Belite Bio Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Belite Bio Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $234

PRO
HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $245

Why Is Belite Bio Stock Soaring Friday?

This PulteGroup Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday

PRO
Canaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303

PRO
Morgan Stanley Maintains Overweight on Belite Bio, Raises Price Target to $206

People Also Watch

People Also Watch

Belite Bio Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Belite Bio Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMizuho Maintains Outperform on Belite Bio, Raises Price Target to $234

PROHC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $245

Why Is Belite Bio Stock Soaring Friday?

This PulteGroup Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday

PROCanaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303

PROMorgan Stanley Maintains Overweight on Belite Bio, Raises Price Target to $206

People Also Watch

People Also Watch

PRO
Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $234

PRO
HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $245

PRO
Canaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303

PRO
Morgan Stanley Maintains Overweight on Belite Bio, Raises Price Target to $206